Charles Schwab Investment Management Inc. Buys 218,566 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Charles Schwab Investment Management Inc. lifted its holdings in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 15.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,667,422 shares of the company's stock after buying an additional 218,566 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.78% of Hims & Hers Health worth $30,714,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company's stock worth $37,000 after buying an additional 1,603 shares during the period. Quest Partners LLC grew its stake in Hims & Hers Health by 5,944.1% during the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company's stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp bought a new position in Hims & Hers Health during the 2nd quarter worth approximately $111,000. CWM LLC lifted its holdings in Hims & Hers Health by 21.4% during the 3rd quarter. CWM LLC now owns 5,982 shares of the company's stock worth $110,000 after buying an additional 1,054 shares during the last quarter. Finally, Amalgamated Bank lifted its holdings in Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company's stock worth $133,000 after buying an additional 2,354 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

HIMS traded up $1.70 during trading on Wednesday, reaching $33.92. 14,799,370 shares of the stock traded hands, compared to its average volume of 9,872,979. The stock has a market cap of $7.41 billion, a price-to-earnings ratio of 76.14 and a beta of 1.25. Hims & Hers Health, Inc. has a fifty-two week low of $8.09 and a fifty-two week high of $35.02. The stock's 50-day simple moving average is $22.60 and its two-hundred day simple moving average is $20.18.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business's revenue for the quarter was up 77.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.04) earnings per share. Research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the company. Piper Sandler reissued a "neutral" rating and issued a $21.00 price target (up previously from $18.00) on shares of Hims & Hers Health in a report on Tuesday, November 5th. Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a "buy" rating and a $24.00 price target on the stock. TD Cowen restated a "buy" rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Imperial Capital cut Hims & Hers Health from an "outperform" rating to an "in-line" rating in a report on Friday, August 9th. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $21.43.

Insiders Place Their Bets

In other Hims & Hers Health news, CEO Andrew Dudum sold 45,767 shares of the business's stock in a transaction dated Friday, September 20th. The stock was sold at an average price of $16.33, for a total value of $747,375.11. Following the completion of the sale, the chief executive officer now owns 67,015 shares of the company's stock, valued at $1,094,354.95. The trade was a 40.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Oluyemi Okupe sold 269,739 shares of the business's stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $20.31, for a total value of $5,478,399.09. Following the completion of the sale, the chief financial officer now directly owns 145,763 shares of the company's stock, valued at $2,960,446.53. This represents a 64.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 974,495 shares of company stock valued at $22,548,139 over the last quarter. Insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.